InvestSMART

Pro Medicus Limited (ASX:PME)

ALERT: Price-sensitive ASX Announcement for PME
Current share price for PME : $162.130 -94.76 (-36.89%)+
Announcement
Release
24 Nov 2025 10:05AM
Price at Release
$256.890
Full Release
download
Summary
In the AGM 2025 presentation, Pro Medicus Limited, a prominent healthcare IT company, reported substantial growth and financial performance for FY 2025, with revenues up by 31.9% and profit after tax increasing by 39.2%. The company secured significant contracts worth AUD $650 million, including major deals with North American healthcare institutions. Pro Medicus is leveraging its Visage 7 platform's scalability and efficiency for enterprise imaging, achieving successful cloud-based implementations while maintaining a debt-free status. The company is actively integrating AI technologies and has strategic plans for continued expansion, particularly in North America, supported by strong financials and innovative solutions like the Visage Ease VP for Apple Vision Pro.
Key Points
  • Pro Medicus Limited (ASX:PME) is a leading healthcare IT company specializing in enterprise imaging and radiology information system software.
  • For FY 2025, the company reported a revenue increase of 31.9% to $213.0 million and a profit after tax up 39.2% to $115.2 million.
  • Significant contracts and renewals in FY 2025 totaled AUD $650 million, including seven new contracts and two large renewals.
  • The company completed seven cloud-based implementations and remains debt-free with strong cash reserves.
  • Pro Medicus has expanded its footprint in the North American market, with significant deals including a 10-year, $330 million contract with Trinity Health.
  • The company is seeing growing interest in its Visage 7 platform, which is optimized for handling massive data, providing a scalable and efficient solution for enterprise imaging.
  • Pro Medicus continues to leverage AI and new technologies, including partnerships for AI integration and the Visage Ease VP for Apple Vision Pro.
  • The company anticipates completing its 3-year strategic plan by FY 2026 and has set ambitious targets for future growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.